Amarin Corporation Plc has announced the appointment of four non-executive directors in conjunction with the completion of the first tranche of a $60 million private placement. The new board representatives represent the largest investors in the placement and are: James Healy of Sofinnova Ventures; Carl Gordon of OrbiMed Advisors LLC; Eric Aguiar of Thomas, McNerney & Partners; and Srinivas Akkaraju of Panorama Capital.
The company is also decreasing the size of the board from eleven to eight members.
Amarin is an Irish biopharmaceutical company focusing on cardiovascular and central nervous system diseases.
Source:
Amarin press release, 22 May 2008
Copyright 2008 Evernow Publishing Ltd